1009642-46-9Relevant academic research and scientific papers
Truncation and non-natural amino acid substitution studies on HTLV-I protease hexapeptidic inhibitors
Nguyen, Jeffrey-Tri,Zhang, Meihui,Kumada, Henri-Obadja,Itami, Ayako,Nishiyama, Keiji,Kimura, Tooru,Cheng, Maosheng,Hayashi, Yoshio,Kiso, Yoshiaki
, p. 366 - 370 (2008)
The culprit behind adult T-cell leukemia, myelopathy/tropical paraparesis, and a plethora of inflammatory diseases is the human T-cell leukemia virus type 1 (HTLV-I). We recently unveiled a potent hexapeptidic HTLV-I protease inhibitor, KNI-10166, compose
Locking the two ends of tetrapeptidic HTLV-I protease inhibitors inside the enzyme
Zhang, Meihui,Nguyen, Jeffrey-Tri,Kumada, Henri-Obadja,Kimura, Tooru,Cheng, Maosheng,Hayashi, Yoshio,Kiso, Yoshiaki
, p. 6880 - 6890 (2008/12/22)
Adult T-cell leukemia and tropical spastic paraparesis/HTLV-I-associated myelopathy are only some of the more common end results of an infection with a human T-cell leukemia virus type 1 (HTLV-I). Expanding from our previous reports, we synthesized all different permutations of tetrapeptidic HTLV-I protease inhibitors using at least eight P3-cap and five P1′-cap moieties. The inhibitors exhibited over 97% inhibition against HIV-1 protease and a wide range of inhibitory activity against HTLV-I protease.
